anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Ronopterin
Trial phase: Phase 1
SMILES: [H][C@]1([C@@H](O)[C@H](C)O)CNc2nc(N)nc(N)c2N1
Sex: Male
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 16
Group description: Infusion (6 hours) of VAS203 (10 mg/kg)

VAS203: Infusion of NO-Synthase inhibitor VAS203
Eligibility criteria:
Inclusion Criteria:

Informed consent in writing available.
Willing and able to comply with all requirements of the study.
Male, 18 and 45 years (inclusive).
Subject has a body weight between 60 kg and 100 kg, extremes included.
BMI 18 to 27 kg/m2.
Non-smoker
Serum creatinine within reference range (≤1.2 mg/dL) and Cockroft-Gault Clearance > 90 ml/min
Good general health as judged by the Investigator, as determined by medical history, physical examination, vital signs (systolic and diastolic blood pressure and pulse rate) and clinical laboratory parameters (clinical chemistry, hematology, and urinalysis)

Exclusion Criteria:

Clinically significant abnormalities in physical examination, vital signs or clinical laboratory parameters (according to the Investigator's judgment).
Serum glutamate oxaloacetate transaminase or glutamate-pyruvate transaminase > 2-times above the upper limit of normal range.
Subject with Cockcroft-Gault clearance < 90 ml/min.
Clinically significant history of cardiovascular disease or any known present cardiovascular disease.
History of clinically significant neurological, gastrointestinal, renal, hepatic, psychological, pulmonary, metabolic, endocrine, hematological, or other major disorders.
Office blood pressure at screening higher than 160/100 mmHg, or lower than 95/55 mmHg.
Office heart rate at screening after at least 5 minutes outside the range of 50- 99 beats per minute (inclusive).
Concomitant use of OTC medication within 1 week prior to dosing, except use of paracetamol (up to 2 g/day).
Participation in any other clinical study within 30 days prior to inclusion in this -
Intervention: Alfacalcidol
Trial phase: Phase 2
ATC code: A11CC03 | M05BB06
SMILES: C=C1C(=CC=C2CCCC3(C)C2CCC3C(C)CCCC(C)C)CC(O)CC1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: patients were given oral 1α-D3 at dose of 1.5 mcg once daily for 8 weeks in addition to propylthiouracil (PTU) 300 mg daily for 8 weeks as the treatment for Graves' disease with thyrotoxicosis

1α-D3: patients were given PTU and 1α-D3
Eligibility criteria:
Inclusion Criteria:

Patients with Graves' disease and still have not gone into remission
Willing to participate in the research

Exclusion Criteria:

Pregnant patient
Suffered from severe liver disease
Suffered from severe kidney disease
Taking vitamin D substitution therapy
Suffered from another autoimmune disease
Suffered from malignancy
Intervention: Orvepitant maleate
Trial phase: Phase 2
SMILES: Cc1cc(F)ccc1C1CC(N2CCN3C(=O)CCC3C2)CCN1C(=O)N(C)C(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1.O=C(O)C=CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 79
Group description: Orvepitant 10mg tablet, once daily for 12 weeks

Orvepitant Maleate: Tablet, once daily, oral
Eligibility criteria:
Key Inclusion Criteria:

Male and female subjects ≥18 years of age.
Diagnosis of CRC or unexplained cough for at least 1 year (see ACCP/BTS guidelines attached).
An awake average cough frequency of ≥10 coughs/ hour, as assessed using an ACM during the screening period.

Key Exclusion Criteria:

Subjects with respiratory tract infection (<4 weeks prior to study start)
Current smokers or ex-smokers with <6 months' abstinence or cumulative history of >10 pack years
Treatment with Angiotensin Converting Enzyme (ACE) inhibitors within 3 months of screening
FEV1 <80% predicted, measured at screening using spirometry
History of cystic fibrosis, idiopathic pulmonary fibrosis, clinically significant bronchiectasis, moderate to severe asthma, chronic obstructive pulmonary disease (COPD)
Any clinically significant abnormal laboratory test result(s)
Inability to comply with the use of prohibited and allowed medications as described in the protocol.
Intervention: Orvepitant maleate
Trial phase: Phase 2
SMILES: Cc1cc(F)ccc1C1CC(N2CCN3C(=O)CCC3C2)CCN1C(=O)N(C)C(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1.O=C(O)C=CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 78
Group description: Orvepitant 20mg tablet, once daily for 12 weeks

Orvepitant Maleate: Tablet, once daily, oral
Eligibility criteria:
Key Inclusion Criteria:

Male and female subjects ≥18 years of age.
Diagnosis of CRC or unexplained cough for at least 1 year (see ACCP/BTS guidelines attached).
An awake average cough frequency of ≥10 coughs/ hour, as assessed using an ACM during the screening period.

Key Exclusion Criteria:

Subjects with respiratory tract infection (<4 weeks prior to study start)
Current smokers or ex-smokers with <6 months' abstinence or cumulative history of >10 pack years
Treatment with Angiotensin Converting Enzyme (ACE) inhibitors within 3 months of screening
FEV1 <80% predicted, measured at screening using spirometry
History of cystic fibrosis, idiopathic pulmonary fibrosis, clinically significant bronchiectasis, moderate to severe asthma, chronic obstructive pulmonary disease (COPD)
Any clinically significant abnormal laboratory test result(s)
Inability to comply with the use of prohibited and allowed medications as described in the protocol.
Intervention: Orvepitant maleate
Trial phase: Phase 2
SMILES: Cc1cc(F)ccc1C1CC(N2CCN3C(=O)CCC3C2)CCN1C(=O)N(C)C(C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1.O=C(O)C=CC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 79
Group description: Orvepitant 30mg tablet, once daily for 12 weeks

Orvepitant Maleate: Tablet, once daily, oral
Eligibility criteria:
Key Inclusion Criteria:

Male and female subjects ≥18 years of age.
Diagnosis of CRC or unexplained cough for at least 1 year (see ACCP/BTS guidelines attached).
An awake average cough frequency of ≥10 coughs/ hour, as assessed using an ACM during the screening period.

Key Exclusion Criteria:

Subjects with respiratory tract infection (<4 weeks prior to study start)
Current smokers or ex-smokers with <6 months' abstinence or cumulative history of >10 pack years
Treatment with Angiotensin Converting Enzyme (ACE) inhibitors within 3 months of screening
FEV1 <80% predicted, measured at screening using spirometry
History of cystic fibrosis, idiopathic pulmonary fibrosis, clinically significant bronchiectasis, moderate to severe asthma, chronic obstructive pulmonary disease (COPD)
Any clinically significant abnormal laboratory test result(s)
Inability to comply with the use of prohibited and allowed medications as described in the protocol.
Intervention: Melphalan Hydrochloride
Trial phase: Phase 2
SMILES: Cl.NC(Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: Propylene Glycol-Free Melphalan Hydrochloride (Evomela) administered intravenously at 70-100 mg/m2/day on Days -3 and -2 prior to autologous stem cell transplantation

Propylene Glycol-Free Melphalan Hydrochloride: Intravenous Propylene Glycol-Free Melphalan Hydrochloride
Eligibility criteria:
Inclusion Criteria:

Age 18 years or older
Eastern Cooperative Oncology Group Performance Status 0-2

Histologic diagnosis of primary systemic (AL) amyloidosis based on:

Deposition of amyloid material by Congo red stain showing characteristic apple green birefringence AND
Evidence of a clonal plasma cell dyscrasia with monoclonal protein in the serum or urine by immunofixation electrophoresis AND/OR abnormal serum free light chain assay AND/OR clonal plasma cells in the bone marrow exam demonstrated by immunohistochemistry, flow cytometry, or in situ hybridization AND
Evidence of organ involvement
Eligible for treatment with high dose melphalan and stem cell transplantation per institutional guidelines
Ability to understand and willingness to sign informed consent
Pulmonary Function Test demonstrating a diffusion capacity of lung for carbon monoxide ≥ 50%
Left ventricular ejection fraction ≥40%
Systolic blood pressure >90 mm Hg (supine position)
Eastern Cooperative Oncology Group Performance status of 2 or better (unless patient is diagnosed with AL amyloidosis involving the gastrointestinal and peripheral/autonomic nervous systems, then performance status of 3 is acceptable)

Exclusion Criteria:

Previous high-dose melphalan and stem cell transplant
Previous total cumulative dose of oral melphalan > 300 mg
Cytotoxic chemotherapy within the previous 28 days
New York Heart Association ≥3
Decompensated or uncontrolled heart failure
Oxygen dependence
epidermal growth factor receptor < 30 ml/min
Active infection (i.e HIV, Hepatitis B or C)
Pregnancy or breastfeeding
Exposure to another investigational drug within 3-4 weeks prior to start of study treatment
Ongoing alcohol or drug addiction
Unable or unwilling to comply with the protocol
Intervention: Ketamine
Trial phase: Phase 4
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Assignment to this arm involves receiving a single IV infusion of ketamine 0.5 mg/kg given over 45 minutes.

Ketamine: IV infusion of ketamine 0.5 mg/kg administered over 45 minutes.
Eligibility criteria:
Inclusion Criteria:

Men and women between the ages of 18 and 64
Patients admitted to the University of Mississippi Medical Center inpatient psychiatry service with suicidal ideations

Exclusion Criteria:

Lifetime history of schizophrenia or other primary psychotic disorder
Current psychotic or manic symptoms
Substance use disorder within one month of admission
Positive urine toxicology at admission
Any lifetime abuse of ketamine or phencyclidine
Systolic BP >180 mmHg or diastolic BP >110 mmHg
Any patient who has eaten food within 8 hours prior to receiving the ketamine infusion or who has drank clear liquids within 2 hours prior to receiving the infusion
Known central nervous system (CNS) mass
CNS abnormalities
Hydrocephalus
Glaucoma
Acute globe injury
Porphyria
Untreated thyroid disease
Known coronary artery disease with poor functional capacity
Pregnancy
Currently breast-feeding
Intervention: SODIUM CHLORIDE
Trial phase: Phase 4
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Assignment to this arm involves receiving an IV infusion of normal saline over the course of 45 minutes.

Normal Saline: IV infusion of 100 ml of normal saline over 45 minutes.
Eligibility criteria:
Inclusion Criteria:

Men and women between the ages of 18 and 64
Patients admitted to the University of Mississippi Medical Center inpatient psychiatry service with suicidal ideations

Exclusion Criteria:

Lifetime history of schizophrenia or other primary psychotic disorder
Current psychotic or manic symptoms
Substance use disorder within one month of admission
Positive urine toxicology at admission
Any lifetime abuse of ketamine or phencyclidine
Systolic BP >180 mmHg or diastolic BP >110 mmHg
Any patient who has eaten food within 8 hours prior to receiving the ketamine infusion or who has drank clear liquids within 2 hours prior to receiving the infusion
Known central nervous system (CNS) mass
CNS abnormalities
Hydrocephalus
Glaucoma
Acute globe injury
Porphyria
Untreated thyroid disease
Known coronary artery disease with poor functional capacity
Pregnancy
Currently breast-feeding
Intervention: Conivaptan
Trial phase: Phase 1
ATC code: C03XA02
SMILES: Cc1nc2c([nH]1)CCN(C(=O)c1ccc(NC(=O)c3ccccc3-c3ccccc3)cc1)c1ccccc1-2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: All seven patients in this arm will receive conivaptan as described in Interventions.

Conivaptan: Patients will receive 20mg IV of the study drug every 12 hours equaling 40mg/day over 2 days (4 doses total), in addition to the standardized ICH management targets using the PI's version of standardized ICH management targets.Usual standard of care can include sedation and analgesia as needed, elevation of the head of the bed, mannitol and/or saline as needed to reduce ICP, and temperature control with antipyretics such as acetaminophen.

The conivaptan bolus (20mg), which is premixed with 100ml of 5% dextrose in water, is infused (peripherally) over 30 minutes, most commonly through an already placed central line.
Eligibility criteria:
Inclusion Criteria:

Age >18 years old and < 80 years.
Diagnosis of primary ICH > 20 cc in volume.
Enrollment within 48 hours from initial symptoms.
Signed informed consent from the patient or obtained via their legally authorized representative (if the patient is not able to sign the informed consent themselves). The patient's decisional capacity to either provide or refuse consent will be determined using the Glasgow Coma Scale (GCS), which is being assessed at baseline and at 24 hours (+/-6hrs) after enrollment. A potential study participant with a GCS > 14 will be asked to provide their own initial study consent. A GCS ≤ 14 would indicate the need to pursue consent via legally authorized representative.

Exclusion Criteria:

Current need for renal replacement therapy (RRT).
Glomerular filtration rate (GFR) of <30 mL/minute at time of admission.
Participation in another study for ICH or intraventricular hemorrhage.
ICH related to infection, thrombolysis, subarachnoid hemorrhage, trauma or tumor.
Presence of HIV or active fungal infection that is known based on information in the electronic medical record (EMR).
Continued use of digoxin or amlodipine (as recommended by the manufacturer due to cytochrome P450 3A4 "CYP3A" inhibition).
Active hepatic failure as defined by aspartate aminotransferase (AST) >160 units/L and/or alanine transaminase (ALT) >180 units/L, or total bilirubin levels greater than four times normal levels (>4.8mg/dL).
Serum Na+> 145 mmol/L (admission labs or any time prior to recruitment/enrollment).
Unable to receive conivaptan based on contraindications indicated by the manufacturer.
Pregnant or lactating females.
Not expected to survive within 48 hours of admission, or a presumed diagnosis of brain death.
Intervention: Bupivacaine
Trial phase: Phase 2
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 57
Group description: Periarticular infiltration cocktail of 60cc of 0.25% bupivacaine with epinephrine

0.25% Bupivacaine with epinephrine: 0.25% bupivacaine with epinephrine
Eligibility criteria:
Inclusion Criteria:

Patients scheduled to undergo primary unilateral total hip replacement
Patients diagnosed with hip osteoarthritis
Patients failed to improve with conservative measures
Patients willing and able to sign informed consent

Exclusion Criteria:

Revision total hip replacement
Bilateral total hip replacement
Birmingham hip resurfacing
Patients with hepatic/kidney disease
Patients with a known allergy to bupivacaine or other local anesthetics
Intervention: Azathioprine
Trial phase: Phase 2 | Phase 3
ATC code: L04AX01
SMILES: Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 46
Group description: Patients in this group will receive 50 mg of azathioprine, two times each day and gradually increased to maximum dose of 3 g daily with the aim of lymphocytes count less than 1500.

Azathioprine: Patients are started with Azathioprine 50 mg tablets, taken orally twice a day. The medication dose is increased gradually with the aim of lymphocytes count bellow 1500 and to the maximum dose of 3 g Azathioprine per day. Cell blood count is checked once a week in the first month of treatment, once every two weeks in the second month of treatment, and monthly in the third month of treatment to make decision about medication dose.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of neuromyelitis optica spectrum disorder based on the recent guidelines in 2015
Expanded disability status scale between 0 and 7
Age between 18 and 50 years old

Exclusion Criteria:

Pregnancy or lactation during the study
Deciding to leave the study by patient
Lack of consent to enter the study
Lack of cooperation for follow up
Severe side effect of the medication
Treatment with other immunosuppressant medications (including but not limited to cyclophosphamide, mycophenolate mofetil, methotrexate, others) within two months before intervention
Taking any other immunosuppressant or other type of medication (including herbal drugs) without permission of the physician during the study.
Presence of other autoimmune disease (including but not limited to Behcet disease, systemic lupus erythematosus, rheumatoid arthritis, and others)
Presence of liver disorders
Presence of hematologic disorders
Presence of heart failure
Receipt of a live vaccine within 4 weeks prior to intervention
Previous treatment with Azathioporine or Rituximab
History of HIV, hepatitis B, or hepatitis C
Ongoing daily steroid use
History of severe allergic or anaphylactic reaction to monoclonal antibodies
Intervention: Rapastinel
Trial phase: Phase 3
SMILES: CC(O)C(N)C(=O)N1CCCC1C(=O)N1CCCC1C(=O)NC(C(N)=O)C(C)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 617
Group description: Rapastinel 450 milligrams (mg) intravenous (IV) open label weekly or every two weeks, based on investigator's discretion for 52 Weeks.
Eligibility criteria:
Inclusion Criteria:

Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for MDD
Current major depressive episode of at least 8 weeks and not exceeding 18 months in duration at Screening
Have no more than partial response (< 50% improvement) to ongoing treatment with a protocol-allowed antidepressant
If female of childbearing potential, have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test.

Exclusion Criteria:

DSM-5-based diagnosis of any disorder other than MDD that was the primary focus of treatment within 6 months before Screening
Lifetime history of meeting DSM-5 criteria for:
Schizophrenia spectrum or other psychotic disorder
Bipolar or related disorder
Major neurocognitive disorder
Neurodevelopmental disorder of greater than mild severity or of a severity that impacts the participant's ability to consent, follow study directions, or otherwise safely participate in the study
Dissociative disorder
Posttraumatic stress disorder
MDD with psychotic features
Significant suicide risk, as judged by the Investigator.
Intervention: Lovenox
Trial phase: Phase 2
SMILES: CC(=O)NC1C(O)OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC3OC(CO)C(OC4OC(C(=O)O)C(O)C(O)C4OS(=O)(=O)O)C(OS(=O)(=O)O)C3NS(=O)(=O)O)C(O)C2OS(=O)(=O)O)C1O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 27
Group description: A clinical nurse will administer enoxaparin subcutaneously <24 hours after insertion of the central venous catheter and then give enoxaparin subcutaneously every 12 hours until the removal of the catheter.

Enoxaparin: The clinical nurse will give enoxaparin subcutaneously every 12 hours at the currently used starting dose of 0.75 mg/kg for children ≤2 months old or 0.5 mg/kg (maximum of 40 mg) for older children. The 1st dose will be given <24 hours after insertion of the catheter. Doses will be adjusted to target an anti-Xa level of 0.2-0.5 IU/mL.
Eligibility criteria:
Inclusion Criteria

Untunneled CVC inserted in the internal jugular or femoral vein within the past 24 hours
Child anticipated to stay in the pediatric intensive care unit ≥48 hours
CVC anticipated to be required for ≥24 hours
>36 weeks corrected gestational age to <18 years old

Exclusion Criteria

Coagulopathy (i.e., international normalized ratio >2.0, activated partial thromboplastin time >50 seconds or platelet count <50,000/mm3)
Known bleeding disorder
Clinically relevant bleeding as defined by the International Society on Thrombosis and Hemostasis (i.e., Hb decreased ≥2 g/dl in 24 hours, required medical or surgical intervention to restore hemostasis, or in a critical organ system [i.e., retroperitoneum, pulmonary, intracranial or central nervous system])
<60 days from a clinically relevant bleeding as defined above
<7 days after trauma or surgery
Anticipated surgery within 48 hours after insertion of the CVC
Renal failure (i.e., creatinine clearance <30 mL/min)
Presence of epidural catheter
Currently taking an antithrombotic agent (e.g., low molecular weight heparin (LMWH), unfractionated heparin (UFH) at therapeutic doses, Coumadin or aspirin)
Radiologically documented DVT at the site of insertion of the CVC in the previous 6 weeks
Known hypersensitivity to heparin or its components, including pork products
History of heparin-induced thrombocytopenia (HIT) (i.e., positive serotonin release assay)
Currently pregnant
Currently lactating
Prior enrollment in the study
Limitation of care
Intervention: Betamethasone
Trial phase: Not Applicable
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 73
Group description: 10mg oral dexamethasone

oral dexamethasone: Patient will be dosed with either placebo or with the study drug, 10mg oral dexamethasone, to be administered by mouth one time in the ED
Eligibility criteria:
Inclusion Criteria:

Patients included if they had clinical diagnosis of pulpitis/dental apical abscess and physical exam revealed pain with percussion of the affected tooth/teeth plus or minus evidence of periapical abscess (gingival erythema, swelling, draining pus). Written informed consent was obtained from each patient prior to enrollment in the study.-

Exclusion Criteria:

Younger than 18 years old
Immunosuppression : HIV patient, transplant patient, chemotherapy
History of diabetes
Recent (<1 month) or chronic steroid use
Hospitalization required due to intractable vomiting/pain
Pregnancy, self report
Intervention: Dapagliflozin
Trial phase: Phase 4
ATC code: A10BD15 | A10BD21 | A10BD25 | A10BK01
SMILES: CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 15
Group description: Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.

Dapagliflozin: 10 mg, one per day before breakfast during 12 weeks.
Eligibility criteria:
Inclusion Criteria:

Informed consent signed
Patients both sexes, age between 30 and 60 years
Diagnosis of prediabetes according American Diabetes Association criteria (fasting blood glucose levels between 100-126 mg/dl; postprandial blood glucose levels after an oral glucose tolerance test with 75 of oral glucose between 140-199 mg/dl; or glycosylated hemoglobin between 5.7-6.4%)
Diagnosis of prehypertension according (JNC8) Eighth Joint National Committee blood pressure between 120-139/ 80-89 mmHg.

Exclusion Criteria:

Women with confirmed or suspected pregnancy
Women under lactation and/or puerperium
Hypersensibility to ingredients of intervention
Physical impossibility for taking pills
Known uncontrolled renal, hepatic, heart or thyroid diseased
Diabetes diagnosis
Previous treatment for glucose or blood pressure Triglycerides ≥400 mg/dL
Total cholesterol ≥240 mg/dL
History of cardiovascular disease
Worker per shift / night